What is HC Wainwright’s Forecast for HRTX Q4 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at HC Wainwright issued their Q4 2026 earnings estimates for Heron Therapeutics in a report released on Wednesday, June 3rd. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.05) per share.

A number of other analysts have also issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Finally, Needham & Company LLC lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Heron Therapeutics presently has a consensus rating of “Hold” and an average target price of $2.50.

Heron Therapeutics Trading Down 0.7%

HRTX opened at $0.45 on Thursday. The firm has a market capitalization of $84.57 million, a P/E ratio of -2.48 and a beta of 1.58. The firm’s 50 day moving average is $0.92 and its 200-day moving average is $1.11. Heron Therapeutics has a 52-week low of $0.43 and a 52-week high of $2.30. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Heron Therapeutics had a negative net margin of 20.53% and a negative return on equity of 7,747.30%. The business had revenue of $34.71 million during the quarter, compared to analysts’ expectations of $36.72 million.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors have recently bought and sold shares of HRTX. Orbimed Advisors LLC acquired a new stake in Heron Therapeutics in the first quarter worth about $7,855,000. Clearline Capital LP lifted its holdings in Heron Therapeutics by 1,033.1% in the third quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock worth $12,238,000 after purchasing an additional 8,855,361 shares during the period. Millennium Management LLC lifted its holdings in Heron Therapeutics by 2,785.2% in the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after purchasing an additional 6,921,405 shares during the period. Baker BROS. Advisors LP acquired a new stake in Heron Therapeutics in the third quarter worth about $5,357,000. Finally, Tang Capital Management LLC lifted its holdings in Heron Therapeutics by 81.2% in the fourth quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock worth $8,125,000 after purchasing an additional 2,800,000 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.